Allied (Allied) EBITDA Margin % : 0.00% (As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allied EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Allied's EBITDA for the three months ended in Feb. 2024 was $-0.63 Mil. Allied's Revenue for the three months ended in Feb. 2024 was $0.00 Mil. Therefore, Allied's EBITDA margin for the quarter that ended in Feb. 2024 was 0.00%.

Allied EBITDA Margin % Historical Data

The historical data trend for Allied's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allied EBITDA Margin % Chart

Allied Annual Data

Trend

Mar18

Mar19

Aug20

Aug21

Aug22

Aug23

EBITDA Margin %

Get a 7-Day Free Trial

-60,362.50

-8,567.47

-13,437.50

Allied Quarterly Data
	Mar19	Jun19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-242,500.00	-3,105.26	-

Competitive Comparison of Allied's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allied's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Allied's EBITDA Margin % falls into.

Allied EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Allied's EBITDA Margin % for the fiscal year that ended in Aug. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Aug. 2023 )	/	Revenue (A: Aug. 2023 )
	=	-9.675	/	0.072
	=	-13,437.50 %

Allied's EBITDA Margin % for the quarter that ended in Feb. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-0.627	/	0
	=	%

Allied (OTCPK:ALID) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Allied EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Allied's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allied (Allied) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Corp (OTCPK:ALID) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1405 St. Paul Street, Suite 201, Kelowna, BC, CAN, V1Y 9N2

Website

https://www.allied.health

Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised ofsales ofcannabis products.

Executives

James George Robinson	director, 10 percent owner	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Anthony Zelen	director, 10 percent owner	1406 MINE HILL LANE, KELOWNA A1 V1P 1S5
Calum Hughes	director, 10 percent owner, officer: Chief Executive Officer	1847 CROSSGLEN COURT, KELOWNA A1 V1V 1S4
David Weinkauf	director, 10 percent owner, officer: Chief Business Development Off	192 SIERRA MORENA LANDING, SW CALGARY A0 T3H 4K4
Paul James Bullock	director, 10 percent owner, officer: Chief Operating Officer	1400 ST PAUL ST, SUITE 201, KELOWNA Z4 V1Y9N2